Evidence mapPaperPMID 39875480Full record

ArticleScientific reports2025

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy.

Apisitt Thaiprayoon, Yodpong Chantarasorn, Worrapoj Oonanant, Anongnard Kasorn, Phoomintara Longsompurana, Satita Tapaneeyakorn, Pinpunya Riangrungroj, Fabien Loison, Andrew C Kruse, Matthew P DeLisa and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Apisitt ThaiprayoonBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, 10140, Thailand.
Yodpong ChantarasornDivision of Ophthalmology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
Worrapoj OonanantDepartment of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Dusit, Bangkok, Thailand.
Anongnard KasornDepartment of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Dusit, Bangkok, Thailand.
Phoomintara LongsompuranaBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, 10140, Thailand.
Satita TapaneeyakornNational Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Thailand Science Park, Khlong Luang, Pathumthani, 12120, Thailand.
Pinpunya RiangrungrojNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and TechnologyDevelopment Agency (NSTDA), 111 Thailand Science Park, Phahonyothin Road, Klong Nueng, Klong Luang, Pathumthani, 12120, Thailand.
Fabien LoisonDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Andrew C KruseDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Matthew P DeLisaRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.
Dujduan Waraho-ZhmayevBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, 10140, Thailand. Dujduan.war@kmutt.ac.th.

Funding

National Research Council of Thailand Fiscal year 2024National Research Council of Thailand NRCT5-RGJ63006Navamindradhiraj University Research Fund 03/2563Thailand Science Research and Innovation FRB670016/0164
6 · The paper itself

Abstract

Nanobodies (Nbs) hold great potential to replace conventional antibodies in various biomedical applications. However, conventional methods for their discovery can be time-consuming and expensive. We have developed a reliable protein selection strategy that combines magnetic activated cell sorting (MACS)-based screening of yeast surface display (YSD) libraries and functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) to isolate antigen-specific Nbs from synthetic libraries. This combined process enabled isolation of three unique Nb clones (NbT15, NbT21, and NbT22) that all bound specifically to a target antigen, namely proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as a gain-of-function PCSK9 mutant (D374Y). All three clones bound to PCSK9 and blocked the interaction between the low-density lipoprotein receptor (LDLR) and either wild-type PCSK9 or the D374Y mutant. Overall, our combined protein selection method enables rapid and straightforward identification of potent antigen-specific Nbs in a manner that can be executed in a basic laboratory setting without the need for specialized equipment. We anticipate that our strategy will be a valuable addition to the protein engineering toolkit, allowing development of Nbs or virtually any other synthetic binding protein for a wide range of applications.

Indexed as

Proprotein Convertase 9Single-Domain AntibodiesHumansPeptide LibraryProtein BindingReceptors, LDLPCSK9 protein, humanPeptide LibraryProprotein Convertase 9Receptors, LDLSingle-Domain AntibodiesCamelid antibodyGenetic selectionHigh-throughput screeningHypercholesterolemiaSynthetic antibody libraryVHH single-domain antibody

Identifiers

PMID39875480
PMCPMC11775271

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.